REGENERON PHARMACEUTICALS, INC.
REGN evidence brief
What we can confirm
- BioSniper Score:
- 7.0 / 10
- Market Cap:
- $81.72B
- Lead Asset:
- Dupixent (Phase 4)
What it means
What to watch
Prepared research question
What matters most for REGN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · REGN
Regeneron Pharmaceuticals (REGN) is a biopharmaceutical company with a diversified portfolio spanning immunology, ophthalmology, oncology, and rare diseases, anchored by commercial products like Dupixent and EYLEA HD and supported by a broad late-stage pipeline.
Key risk: Product concentration risk
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 138 clinical trials · 8 catalysts · 1 FDA decision for REGENERON PHARMACEUTICALS, INC..
Regeneron Pharmaceuticals (REGN) is a biopharmaceutical company with a diversified portfolio spanning immunology, ophthalmology, oncology, and rare diseases, anchored by commercial products like Dupixent and EYLEA HD and supported by a broad late-stage pipeline.
- Cash & equivalents of $2,455.8M as of 2026-06-30 [sec]
- Total revenue of $4,290.7M as of 2026-06-30 [sec]
- Net income of $1,296.9M as of 2026-06-30 [sec]
- Shareholders' equity of $31,711.4M as of 2026-06-30 [sec]
- Received FDA approval for Pasatru (garetosmab) in adult fibrodysplasia ossificans progressiva in August 2026 [news]
What works
- Strong commercial momentum from Dupixent and EYLEA HD, with executives highlighting continued growth across key marketed products [news]
- Broad late-stage pipeline with multiple Phase 3 starts scheduled through 2027, including programs in MASLD, FOP, and oncology [catalyst]
- Recent FDA approval of Pasatru adds a new rare disease therapy and revenue stream to the portfolio [news]
- Deepening collaboration with Biohaven in oncology, including a clinical supply agreement for cemiplimab combination trials [news]
What to weigh
- Reliance on a few key products (Dupixent, EYLEA HD) for revenue growth, with pipeline programs still in early or mid-stage development [news]
- Competitive pressure in ophthalmology and immunology markets may impact EYLEA HD and Dupixent growth [news]
- Rare disease approvals like Pasatru address small patient populations, limiting revenue scale [news]
From the filings
Quoted directly from source documents.
Regeneron received FDA approval for Pasatru in adult FOP
“Regeneron Pharmaceuticals (NasdaqGS: REGN) received FDA approval for Pasatru TM (garetosmab grts) to treat adults with fibrodysplasia ossificans progressiva.”
News · August 29, 2026
Regeneron and Biohaven deepened oncology collaboration
“Biohaven announced a clinical supply agreement with Regeneron to evaluate the combination of BHV-1530 and Regeneron’s cemiplimab (Libtayo) in patients with solid tumors.”
News · August 14, 2026
Catalyst timeline
- 2026-10-15 · Phase2_Start: Phase 2 Platform Trial of Combination Therapies for Participants With Locally Advanced Basal Cell Carcinoma: Master Protocol With Cemiplimab Monotherapy as Comparator Arm — Evaluates combination therapies with cemiplimab in basal cell carcinoma.
- 2026-10-23 · Phase2_Start: Phase 1/2 Open-Label Trial With Extended Follow-Up to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Multiple Doses of ALN-6457 in Participants With Symptomatic Prion Disease — First-in-human study of ALN-6457 for prion disease.
- 2026-10-30 · Phase2_Start: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 52-Week Trial to Investigate the Efficacy and Safety of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity — Tests olatorepatide in hidradenitis suppurativa with metabolic focus.
- 2026-11-02 · Phase1_Start: A Phase 1, Single-Ascending Dose Study of REGN24493, an Anti-TSHR Monoclonal Antibody, in Participants With Graves' Disease — First-in-human study of REGN24493 for Graves' disease.
- 2026-11-06 · Phase3_Start: A Phase 3, Randomized, Double-blind, Placebo-controlled Trial of ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) — Phase 3 trial of ALN-CIDEB for MASLD.
- 2026-11-23 · Phase2_Start: A Phase 1/2 Study of REGN13089-M404-M2980, a MET-targeting Antibody-Drug Conjugate in Adult Participants With Previously Treated Advanced Solid Tumors — First-in-human study of a MET-targeting ADC.
- 2027-02-02 · Phase3_Start: Phase 3 Evaluation of the Safety, Pharmacokinetics, and Efficacy of Garetosmab (Anti-Activin A Monoclonal Antibody) in Children and Adolescents With Fibrodysplasia Ossificans Progressiva — Pediatric Phase 3 trial for garetosmab in FOP.
- 2027-06-28 · Phase2_Start: Phase 1/2 Trial of REGN21353 (a STEAP1xCD3 Bispecific Antibody) Administered Alone or in Combination With Nezastomig (a PSMAxCD28 Bispecific Antibody) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Combination bispecific antibody trial for prostate cancer.
Risks & what to watch (3)›
Key risks
- Product concentration risk — Revenue growth is heavily tied to Dupixent and EYLEA HD; pipeline diversification is still in progress [news]
- Competitive pressure — Ophthalmology and immunology markets face competition that could affect EYLEA HD and Dupixent [news]
- Rare disease revenue scale — Pasatru addresses a small patient population, limiting near-term revenue impact [news]
What to watch
- Phase 3 start of ALN-CIDEB in MASLD on 2026-11-06 [catalyst]
- Phase 3 start of garetosmab in pediatric FOP on 2027-02-02 [catalyst]
- Commercial performance of Dupixent and EYLEA HD in upcoming quarters [news]
- Progress of the Biohaven combination trial with cemiplimab [news]
Sources: Catalysts · News · Generated October 11, 2026 · How we verify sources →
Run REGENERON PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available REGENERON PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.32 · 3% dilution
Lead: Approved
3 candidates
8 upcoming, next in ~1d
0 buys · 15 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1,384
Total value held
$64.67B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 8,947,735 | $6.91B |
| vanguard capital management llc | 6,654,913 | $5.14B |
| state street corp | 4,664,478 | $3.60B |
| dodge & cox | 4,458,238 | $3.44B |
| jpmorgan chase & co | 4,311,806 | $3.23B |
| franklin resources inc | 2,722,071 | $2.10B |
| geode capital management, llc | 2,607,732 | $2.01B |
| nuveen, llc | 2,065,064 | $1.60B |
| loomis sayles & co l p | 1,912,310 | $1.48B |
| wellington management group llp | 1,837,459 | $1.42B |
Showing top 10 of 1,384 institutional holders of REGENERON PHARMACEUTICALS, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 1, 2026- % of float
- 2.8%
- Days to cover
- 4.5
- Shares short
- 2,841,780
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
REGN short interestGovernance
Frequently asked questions
What is the AI investment thesis for REGENERON PHARMACEUTICALS, INC.?
Regeneron Pharmaceuticals (REGN) is a biopharmaceutical company with a diversified portfolio spanning immunology, ophthalmology, oncology, and rare diseases, anchored by commercial products like Dupixent and EYLEA HD and supported by a broad late-stage pipeline.
What is REGENERON PHARMACEUTICALS, INC.'s lead drug candidate?
REGENERON PHARMACEUTICALS, INC.'s most advanced tracked candidate is Dupixent (Phase 4) for Chronic Rhinosinusitis With Nasal Polyposis.
What is REGENERON PHARMACEUTICALS, INC.'s next catalyst?
REGENERON PHARMACEUTICALS, INC.'s next tracked catalyst is a Phase2_Start event — "Phase2_Start: Phase 2 Platform Trial of Combination Therapies for Participants With Locally Advanced Basal Cell Carcinoma: Master Protocol With Cemiplimab Monotherapy as Comparator Arm" — expected October 15, 2026.
Who is the CEO of REGENERON PHARMACEUTICALS, INC.?
Dr. Leonard S. Schleifer M.D., Ph.D. is the chief executive officer of REGENERON PHARMACEUTICALS, INC. (REGN).
Where is REGENERON PHARMACEUTICALS, INC. headquartered?
REGENERON PHARMACEUTICALS, INC. (REGN) is headquartered in Tarrytown, NY, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.